Delivery Order SPE2DR25D3003-SPE2DR26F5QR5
- Not listed
- The Defense Logistics Agency awarded a $1,140.45 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 6, 2026, for the supply of Insulin Aspart 100 Unit/mL in 10mL vials. This non-set-aside competitive award will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of January 7, 2026. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, a...
- The Defense Logistics Agency awarded a delivery order valued at $1,699.68 to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL in 10mL vials. This non-competitive, firm fixed price delivery order was awarded on December 1, 2025, with an ultimate completion date of December 2, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child delivery order issued under...
- The U.S. Department of Defense's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $1,463.20 for Insulin Aspart 100 Unit/mL vials (10mL) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10mL) with a ceiling value of $1,197.73. This is a firm fixed price delivery order with no set-aside designation, meaning the contract was competitively awarded. The performance location is AmerisourceBergen's Corporate Office in Conshohocken, Pennsylvania, with an ultimate completion date of June 3, 2025. This delivery order represents a child...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,385.42 on August 19, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10mL). This firm fixed-price delivery order, with an ultimate completion date of August 20, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award was made through competitive procurement with no set-aside designation. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $1,416.40 to AmerisourceBergen Drug Corp on November 28, 2025, for the supply of Insulin Aspart 100 Unit/mL in 10mL vials. This is a firm fixed-price delivery order with an ultimate completion date of December 1, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued as a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $4,205.06 to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL vials (10mL) on August 28, 2025, with completion scheduled for August 29, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract is classified as a child award under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10 mL) with a ceiling value of $1,463.20. This is a firm fixed price delivery order with an ultimate completion date of October 24, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued...
- The Defense Logistics Agency has awarded a delivery order valued at $2,671.90 to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/ML in 10 ML vials. This firm fixed price delivery order, issued on December 5, 2025, with an ultimate completion date of December 8, 2025, represents a routine pharmaceutical procurement under the company's existing contract vehicle with DLA. The award is unset-aside and competitively awarded, reflecting AmerisourceBergen's established...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 7, 2025, for the supply of Insulin Aspart 100 Unit/mL vials in 10mL quantities, with a ceiling value of $1,257.13 and an ultimate completion date of December 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award...
- SPE2DR25D3003Indefinite Delivery Contract
- SPE2DR25D3003-SPE2DR26F5QR5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,521.39 to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL vials (10mL) on January 6, 2026, with an ultimate completion date of January 7, 2026. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a task order under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), which serves as a comprehensive global pharmaceutical support vehicle enabling delivery of a broad range of medications and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor and critical vendor for federal medical procurement serving military and veteran healthcare systems. The company has demonstrated extensive capability in fulfilling diverse pharmaceutical deliveries through competitive federal contracting, with a portfolio spanning diabetes medications, specialty treatments, vaccines, and medical devices across multiple therapeutic domains. This specific insulin delivery is consistent with the company's ongoing role as a primary supplier of essential pharmaceutical commodities to the Defense Health Agency and other federal healthcare institutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 1/5/26 |